Pseudomonas vaccine - Berna Biotech

Drug Profile

Pseudomonas vaccine - Berna Biotech

Alternative Names: Aerugen

Latest Information Update: 19 Jul 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Berna Biotech
  • Class Bacterial vaccines; Pseudomonas vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pseudomonal infections

Highest Development Phases

  • Discontinued Pseudomonal infections

Most Recent Events

  • 18 Jul 2006 Discontinued - Phase-III for Pseudomonal infections in Europe (IM)
  • 04 Aug 2005 Aerugen® has been licensed to Solvay Pharmaceuticals in the US, Canada, Latin America and other international markets
  • 27 Jun 2005 Aerugen® has been licensed to CSL in Australia and New Zealand
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top